Development of an autoimmune syndrome affecting the skin and internal organs in P-selectin glycoprotein ligand 1 leukocyte receptor-deficient mice

Arthritis and Rheumatology

Volumn 66, Issue 11, 2014, Pages 3178-3189

  Perez Frias A ^a   Gonzalez Tajuelo R ^a   Nunez Andrade N ^a   Tejedor, R ^a   Garcia Blanco M J ^a   Vicente Rabaneda, E ^a   Castaneda S ^a   Gamallo, C ^a   Silvan J ^a   Esteban Villafruela, A ^a   Cubero Rueda, L ^a   Garcia Garcia C ^a   Munoz Calleja C ^a   Garcia Diez A ^a   Urzainqui, A ^a  

^a Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; P SELECTIN GLYCOPROTEIN LIGAND 1; MEMBRANE PROTEIN; P-SELECTIN LIGAND PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BIOCHEMICAL ANALYSIS; CELL ISOLATION; COLLAGEN FIBER; CONNECTIVE TISSUE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HISTOLOGY; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; KIDNEY INFARCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SERUM; SKIN BLOOD VESSEL; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; URINE; VASCULAR DISEASE; ANIMAL; C57BL MOUSE; CONNECTIVE TISSUE DISEASES; DEFICIENCY; DISEASE MODEL; FIBROSIS; GENETICS; KIDNEY; KIDNEY DISEASES; KNOCKOUT MOUSE; LUNG; LUNG DISEASES, INTERSTITIAL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; SKIN; SKIN DISEASES;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CONNECTIVE TISSUE DISEASES; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; KIDNEY; KIDNEY DISEASES; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PREVALENCE; SCLERODERMA, SYSTEMIC; SKIN; SKIN DISEASES;

EID: 84925581201     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38808     Document Type: Article

References (50)

1. Mayes MD,. Scleroderma epidemiology. Rheum Dis Clin North Am 2003; 29: 239-54.
2. Barnes J, Mayes MD,. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012; 24: 165-70.
3. Grossman C, Dovrish Z, Shoenfeld Y, Amital H,. Do infections facilitate the emergence of systemic sclerosis? Autoimmun Rev 2011; 10: 244-7.
4. Roberts-Thomson PJ, Walker JG,. Stochastic processes in the aetiopathogenesis of scleroderma. Intern Med J 2012; 42: 235-42.
5. Chizzolini C, Brembilla NC, Montanari E, Truchetet ME,. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev 2011; 10: 276-81.
6. Gabrielli A, Avvedimento EV, Krieg T,. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
7. Bhattacharyya S, Wei J, Varga J,. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2011; 8: 42-54.
8. Opitz C, Klein-Weigel PF, Riemekasten G,. Systemic sclerosis: a systematic overview. Part 2. Immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension. Vasa 2011; 40: 20-30.
9. Passweg J, Tyndall A,. Autologous stem cell transplantation in autoimmune diseases. Semin Hematol 2007; 44: 278-85.
10. Henes JC, Schmalzing M, Vogel W, Riemekasten G, Fend F, Kanz L, et al., Optimization of autologous stem cell transplantation for systemic sclerosis-a single-center longterm experience in 26 patients with severe organ manifestations. J Rheumatol 2012; 39: 269-75.
11. Spertini O, Cordey AS, Monai N, Giuffre L, Schapira M,. P-selectin glycoprotein ligand 1 is a ligand for L-selectin on neutrophils, monocytes, and CD34+ hematopoietic progenitor cells. J Cell Biol 1996; 135: 523-31.
12. Ley K, Laudanna C, Cybulsky M, Nourshargh S,. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7: 678-89.
13. Walcheck B, Moore KL, McEver RP, Kishimoto TK,. Neutrophil-neutrophil interactions under hydrodynamic shear stress involve L-selectin and PSGL-1: a mechanism that amplifies initial leukocyte accumulation of P-selectin in vitro. J Clin Invest 1996; 98: 1081-7.
14. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS,. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nat Rev Rheumatol 1997; 389: 978-81.
15. Kieffer JD, Fuhlbrigge RC, Armerding D, Robert C, Ferenczi K, Camphausen RT, et al., Neutrophils, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: cutaneous lymphocyte antigen. Biochem Biophys Res Comm 2001; 285: 577-87.
16. Rossi FM, Corbel SY, Merzaban JS, Carlow DA, Gossens K, Duenas J, et al., Recruitment of adult thymic progenitors is regulated by P-selectin and its ligand PSGL-1. Nat Immunol 2005; 6: 626-34.
17. Veerman KM, Williams MJ, Uchimura K, Singer MS, Merzaban JS, Naus S, et al., Interaction of the selectin ligand PSGL-1 with chemokines CCL21 and CCL19 facilitates efficient homing of T cells to secondary lymphoid organs. Nat Immunol 2007; 8: 532-9.
18. Dominguez-Luis M, Lamana A, Vazquez J, Garcia-Navas R, Mollinedo F, Sanchez-Madrid F, et al., The metalloprotease ADAM8 is associated with and regulates the function of the adhesion receptor PSGL-1 through ERM proteins. Eur J Immunol 2011; 41: 3436-42.
19. H1 T-cell responses. J Allergy Clin Immunol 2011; 127: 787-94.e9.
20. Schakel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J, et al., 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 2002; 17: 289-301.
21. Spertini C, Baisse B, Spertini O,. Ezrin-radixin-moesin-binding sequence of PSGL-1 glycoprotein regulates leukocyte rolling on selectins and activation of extracellular signal-regulated kinases. J Biol Chem 2012; 287: 10693-702.
22. Urzainqui A, Martinez del Hoyo G, Lamana A, de la Fuente H, Barreiro O, Olazabal IM, et al., Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells. J Immunol 2007; 179: 7457-65.
23. Urzainqui A, Serrador JM, Viedma F, Yanez-Mo M, Rodriguez A, Corbi AL, et al., ITAM-based interaction of ERM proteins with Syk mediates signaling by the leukocyte adhesion receptor PSGL-1. Immunity 2002; 17: 401-12.
24. Angiari S, Rossi B, Piccio L, Zinselmeyer BH, Budui S, Zenaro E, et al., Regulatory T cells suppress the late phase of the immune response in lymph nodes through P-selectin glycoprotein ligand-1. J Immunol 2013; 191: 5489-500.
25. He X, Schoeb TR, Panoskaltsis-Mortari A, Zinn KR, Kesterson R, Zhang J, et al., Deficiency of P-selectin or P-selectin glycoprotein ligand-1 leads to accelerated development of glomerulonephritis and increased expression of CC chemokine ligand 2 in lupus-prone mice. J Immunol 2006; 177: 8748-56.
26. Nunez-Andrade N, Lamana A, Sancho D, Gisbert JP, Gonzalez-Amaro R, Sanchez-Madrid F, et al., P-selectin glycoprotein ligand-1 modulates immune inflammatory responses in the enteric lamina propria. J Pathol 2011; 224: 212-21.
27. Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, Akiyama Y, et al., Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 2010; 185: 2502-15.
28. Estrada-Capetillo L, Hernandez-Castro B, Monsivais-Urenda A, Alvarez-Quiroga C, Layseca-Espinosa E, Abud-Mendoza C, et al., Induction of Th17 lymphocytes and Treg cells by monocyte-derived dendritic cells in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Dev Immunol 2013; 2013: 584303.
29. Dunne JV, van Eeden SF, Keen KJ,. L-selectin and skin damage in systemic sclerosis. PLoS One 2012; 7: e44814.
30. Iversen LV, Ostergaard O, Ullman S, Nielsen CT, Halberg P, Karlsmark T, et al., Circulating microparticles and plasma levels of soluble E- and P-selectins in patients with systemic sclerosis. Scand J Rheumatol 2013; 42: 473-82.
31. Yamamoto T,. Animal model of systemic sclerosis. J Dermatol 2010; 37: 26-41.
32. Beyer C, Schett G, Distler O, Distler JH,. Animal models of systemic sclerosis: prospects and limitations [review]. Arthritis Rheum 2010; 62: 2831-44.
33. Lafyatis R, York M,. Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol 2009; 21: 617-22.
34. Stummvoll GH, Aringer M, Grisar J, Steiner CW, Smolen JS, Knobler R, et al., Increased transendothelial migration of scleroderma lymphocytes. Ann Rheum Dis 2004; 63: 569-74.
35. Guiducci S, Giacomelli R, Cerinic MM,. Vascular complications of scleroderma. Autoimmun Rev 2007; 6: 520-3.
36. Hasegawa M,. B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis. J Dermatol 2010; 37: 3-10.
37. Hussein MR, Hassan HI, Hofny ER, Elkholy M, Fatehy NA, Abd Elmoniem, AE, et al. Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1β, and tumour necrosis factor α in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 2005; 58: 178-84.
38. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-52.
39. Nakahara M, Nagayama Y, Ichikawa T, Yu L, Eisenbarth GS, Abiru N,. The effect of regulatory T-cell depletion on the spectrum of organ-specific autoimmune diseases in nonobese diabetic mice at different ages. Autoimmunity 2011; 44: 504-10.
40. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, et al., Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008; 28: 687-97.
41. Hamaguchi Y,. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol 2010; 37: 4253.
42. Sticherling M,. Systemic sclerosis: dermatological aspects. Part 1. Pathogenesis, epidemiology, clinical findings. J Dtsch Dermatol Ges 2012; 10: 705-18.
43. Schroeder K, Herrmann M, Winkler TH,. The role of somatic hypermutation in the generation of pathogenic antibodies in SLE. Autoimmunity 2013; 46: 121-7.
44. Zhang J, Jacobi AM, Wang T, Diamond B,. Pathogenic autoantibodies in systemic lupus erythematosus are derived from both self-reactive and non-self-reactive B cells. Mol Med 2008; 14: 675-81.
45. Caron M, Hudson M, Baron M, Nessim S, Canadian Scleroderma Research Group, Steele R,. Longitudinal study of renal function in systemic sclerosis. J Rheumatol 2012; 39: 1829-34.
46. Iaccarino L, Gatto M, Bettio S, Caso F, Rampudda M, Zen M, et al., Overlap connective tissue disease syndromes. Autoimmun Rev 2013; 12: 363-73.
47. Distler JH, Gay S, Distler O,. Angiogenesis and vasculogenesis in systemic sclerosis [published erratum appears in Rheumatology (Oxford) 2008;47:234-5]. Rheumatology (Oxford) 2006; 45 Suppl 3: iii26-7.
48. Rabquer BJ, Koch AE,. Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 2012; 14: 56-63.
49. Shahane A,. Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis. Rheumatol Int 2013; 33: 1655-67.
50. Del Galdo F, Matucci-Cerinic M,. The search for the perfect animal model discloses the importance of biological targets for the treatment of systemic sclerosis. Ann Rheum Dis 2014; 73: 635-6.